Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07823842) titled 'T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD' on Sept. 8.

Study Type: Observational [Patient Registry]

Primary Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Condition: Asthma COPD (Chronic Obstructive Pulmonary Disease)

Intervention: Drug: Biologics targeting Type 2 inflammation

Recruitment Status: Recruiting

Date of First Enrollment: July 30, 2026

Target Sample Size: 538

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07823842

Published by HT Digital Content Services with permission from Health Daily ...